Boulder Neurosurgical Associates, Boulder, Colorado, USA; Justin Parker Neurological Institute, Boulder, Colorado, USA.
Boulder Neurosurgical Associates, Boulder, Colorado, USA.
World Neurosurg. 2021 Feb;146:e1377-e1383. doi: 10.1016/j.wneu.2020.12.016. Epub 2020 Dec 11.
The main objective of this study was to analyze the ability of local anesthetic instillation into the retropharyngeal space to reduce dysphagia symptoms and occurrence rates in patients undergoing anterior cervical discectomy and fusion (ACDF) procedures.
A single-center, prospective, randomized, double-blinded, and placebo-controlled clinical study was performed. We enrolled patients undergoing one- or two-level ACDF procedures for cervical degenerative disc disease with disc herniation, radiculopathy and/or myelopathy symptoms. The patients were randomly assigned (1:1 ratio) to receive either 0.5% bupivacaine hydrochloride or 0.9% NaCl solution.
Forty-three (74%) and 41 (77%) of patients reported dysphagia symptoms at the time of discharge in the investigational and control groups, respectively. There were no statistically significant differences in duration of dysphagia symptoms, Swallowing-Quality of Life (SWAL-QOL) survey or pain scores between the investigational and control patient groups at any of the follow-up time points. Controlling for independent variables, only younger age significantly predicted dysphagia symptoms at discharge, 2-week, and 3-month follow-ups (P ≤ 0.03; R ≥ -0.038; OR 0.96, 95% CI 0.93-0.99. Female sex was associated with lower SWAL-QOL scores at discharge (P = 0.046; R = 0.87; OR 2.38, 95% CI 1.02-5.56). A total of 8 (13.8%) and 6 (11.3%) patients in the investigational and control groups, respectively, were referred to a specialist or underwent speech therapy for their dysphagia symptoms. There were no adverse reactions to the study drug observed.
Local retropharyngeal space anesthetic instillation did not reduce dysphagia symptoms or occurrence rates in patients undergoing anterior discectomy and fusion surgeries.
本研究的主要目的是分析将局部麻醉剂注入咽后间隙以减少行前路颈椎间盘切除融合术(ACDF)的患者吞咽困难症状和发生率的能力。
进行了一项单中心、前瞻性、随机、双盲、安慰剂对照的临床研究。我们招募了因颈椎退行性椎间盘疾病伴椎间盘突出、神经根病和/或脊髓病症状而行单节段或双节段 ACDF 手术的患者。患者以 1:1 的比例随机分配接受 0.5%盐酸布比卡因或 0.9%生理盐水。
研究组和对照组分别有 43 例(74%)和 41 例(77%)患者在出院时报告有吞咽困难症状。在任何随访时间点,研究组和对照组患者的吞咽困难症状持续时间、吞咽生活质量(SWAL-QOL)调查或疼痛评分均无统计学差异。在控制了独立变量后,只有年龄较小显著预测了出院、2 周和 3 个月随访时的吞咽困难症状(P≤0.03;R≥-0.038;OR 0.96,95%CI 0.93-0.99)。女性与出院时较低的 SWAL-QOL 评分相关(P=0.046;R=0.87;OR 2.38,95%CI 1.02-5.56)。研究组和对照组分别有 8 例(13.8%)和 6 例(11.3%)患者因吞咽困难症状转诊给专家或接受了言语治疗。未观察到研究药物的不良反应。
在接受前路椎间盘切除融合术的患者中,局部咽后间隙麻醉剂注射并未减少吞咽困难症状或发生率。